PPIDT00061
Drug Information
| Name | Trastuzumab |
|---|---|
| Sequence | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
| DrugBank_ID | DB00072 |
| Type | biotech |
| Indication | For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based therapy.[L14015] Trastuzumab is indicated as a first-line treatment, in combination with paclitaxel, for metastatic HER2-overexpressing breast cancer, and as monotherapy in patients who have previously received one or more chemotherapy regimens in the metastatic setting.[L14015] In Europe, trastuzumab can also be used in combination with paclitaxel or docetaxel for the treatment of metastatic HER2-positive breast cancer in adult patients and with an aromatase inhibitor in postmenopausal patients.[L49324] For HER2-positive early breast cancer, the EMA approved trastuzumab as monotherapy following surgery, chemotherapy (neoadjuvant or adjuvant), and radiation or following adjuvant chemotherapy with doxorubicin and cyclophosphamide in combination with paclitaxel or docetaxel. It can also be used in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin or with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy for locally advanced (including inflammatory) disease or tumors > 2 cm in diameter.[L49324] Trastuzumab is also indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease by the FDA and EMA.[L14015] Trastuzumab is indicated for subcutaneous administration - in combination with either [hyaluronidase][L14132] or both hyaluronidase and [pertuzumab][L14510] - for the treatment of adults with HER2-positive breast cancers. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Powder, for solution | Intravenous |
420 mg / vial
|
| Injection, solution | Intravenous |
150 mg
|
| — | Intravenous |
420 mg/20mL
|
| Injection | Intravenous |
150 mg/7.4mL
|
| Injection | Parenteral |
600 MG/5ML
|
| Injection, powder, lyophilized, for solution | Intravenous |
150 mg/7.4mL
|
| Injection, solution | Parenteral; Subcutaneous |
600 MG
|
| Injection, solution | Parenteral; Subcutaneous |
600 MG/5ML
|
| Powder, for solution | Intravenous |
440 mg / vial
|
| Solution | Intravenous |
|
| Injection, solution | — |
600 mg/5ml
|
| Injection, powder, lyophilized, for solution | Intravenous |
44000000 mg
|
| Injection, solution | Subcutaneous |
600 mg/5mL
|
| Injection, solution | Subcutaneous |
|
| Injection, powder, for solution | Intravenous |
440 mg
|
| Solution | Subcutaneous |
600 mg / 5 mL
|
| Solution | Subcutaneous |
600.00 mg
|
| Injection, solution | Subcutaneous |
600 mg
|
| Injection, powder, for solution | Intravenous |
|
| Solution | Subcutaneous |
600 mg
|
| Solution | Subcutaneous |
60000000 mg
|
| Injection, powder, for solution | — |
440 mg
|
| Injection, powder, for solution | — |
440 mg/20ml
|
| Injection, powder, for solution | Intravenous |
420 mg
|
| Kit; powder, for solution | Intravenous |
440 mg / vial
|
| Solution | Intravenous |
150.00 mg
|
| Injection, powder, for solution | Intravenous |
150 mg/1vial
|
| Injection, solution, concentrate | Intravenous |
150 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
15000000 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
150 mg
|
| Injection, powder, for solution | — |
100 mg
|
| Injection, powder, for solution | — |
160 mg
|
| Injection, powder, for solution | — |
160 mg/1vial
|
| Injection, powder, lyophilized, for solution | Intravenous |
150 mg/7.15mL
|
| Injection, powder, lyophilized, for solution | Intravenous |
420 mg/20mL
|
| Kit; powder, for solution | Intravenous |
420 mg / vial
|
| Injection, powder, for solution | — |
150 mg
|
| Injection, powder, for solution | Intravenous |
150 mg
|
| Injection, powder, for solution | Intravenous; Parenteral |
150 MG
|
| Powder, for solution | Intravenous |
|
| Powder, for solution | Intravenous |
150 mg / vial
|
| Injection, powder, for solution | Intravenous; Parenteral |
420 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
150 mg/1
|
| Kit | Intravenous |
420 mg/1
|
| Powder, for solution | Intravenous |
150 mg
|
| Powder, for solution | Intravenous |
420 mg
|
| Kit; powder, for solution; solution | Intravenous |
|
| Solution | Subcutaneous |
|
| Solution | Subcutaneous |
6000000 mg
|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
420 mg/20mL
|
| Injection, solution, concentrate | Intravenous |
150 mg/1vial
|
| Injection, solution, concentrate | Intravenous |
440 mg/1vial
|
| Injection, powder, lyophilized, for solution | Intravenous |
440 mg
|
| Injection, powder, for solution | Intravenous |
44000000 mg
|
| Solution | Intravenous |
440.00 mg
|
| Injection, powder, for solution; injection, powder, lyophilized, for solution | Intravenous |
440 mg/20ml
|
| — | Intravenous |
420 mg
|
| Injection, powder, for solution | Intravenous |
60 mg
|
| Injection, powder, for solution | Intravenous; Parenteral |
60 mg
|
| Solution | Intravenous |
|
| Injection, powder, for solution | Intravenous |
440 mg/1vial
|
| Powder | Intravenous |
440 mg/1bottle
|
| Powder | Intravenous |
150 mg/1vial
|
| Powder | Intravenous |
150 mg/1bottle
|
| Injection, powder, for solution | — |
100 mg/1vial
|